Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Axial Spondyloarthritis - Global Drug Forecast & Market Analysis to 2028 - ResearchAndMarkets.com

November 19, 2019 GMT

DUBLIN--(BUSINESS WIRE)--Nov 19, 2019--

The “Axial Spondyloarthritis: Global Drug Forecast and Market Analysis to 2028” report has been added to ResearchAndMarkets.com’s offering.

The axSpA market has historically been reliant on anti-tumor necrosis factor (TNF) therapies that have been available for over a decade, and the pipeline for drugs in late-stage development was lacking, but recent developments have led to research on novel treatment mechanisms. This will be vital in treating the underdiagnosed nr-axSpA population.

In January 2016, Novartis gained approval for Cosentyx (secukinumab), the first-in-class interleukin (IL)-17 inhibitor that was the first new biologic treatment approved for AS that was not an anti-TNF. Moreover, biosimilars of currently marketed anti-TNF biologics recently entered the market, with Remicade (infliximab) biosimilars first marketed in 2015 in Europe. This is likely to result in a highly competitive market for patients who have failed multiple non-steroidal anti-inflammatory drugs (NSAIDs).

Competition will intensify with the arrival of new anti-IL-17 treatments and a new class of therapies in development, Janus kinase (JAK) inhibitors, which will offer a more convenient form of administration. With existing unmet need for all patients, particularly nr-axSpA patients, being diagnosed in a timely manner and having treatment options that are not solely subcutaneously or intravenously administered, axSpA represents an increasingly important rheumatology sector for drug developers.

The research estimates that sales of drugs in the axSpA market were approximately $3.1B in 2018 in the 7MM. The US was the largest market, with approximately $2.3B in drug sales, which represented 75.3% of the total axSpA market. The 5EU market contributed $705M in sales and Japan contributed sales of $54M in 2018.

Global sales in the axSpA market are expected to grow to $3.6B by 2028, at a Compound Annual Growth Rate (CAGR) of 1.5% from 2018-2028. The report forecasts the US to grow to $2.7B (74.7% of global sales), the 5EU to grow to $850M (23.9% of global sales), and Japan to shrink to $52M (1.5% of global sales) over the next 10 years.

Key Questions Answered

Key Highlights

The greatest driver of growth in the global axSpA market will be the launches of five pipeline therapies during the forecast period. The entry of these anticipated therapies, including Eli Lilly’s Taltz and Pfizer’s tofacitinib, will be subject to moderate uptake among the AS and nr-axSpA populations.

The main barrier to growth in the axSpA market will be the patent expiry, and subsequent launch of biosimilars of Humira (adalimumab) in the US, and the genericization of tofacitinib in the latter half of the forecast across the 7MM.

The most important unmet needs in axSpA are the need for speedier diagnosis and convincing patients to start biologic therapy. The former is being addressed by the increasingly routine use of MRI instead of X-ray to diagnose patients, and the greater understanding and awareness of nr-axSpA. The latter is impacted by poor patient education about their disease and a fear of subcutaneous/intravenous injection.

Factors driving a low biologic therapy treatment rate include some negative or fearful attitudes towards subcutaneously/intravenously administered therapeutics, nr-axSpA patients not perceiving themselves as severe enough to warrant biologic treatment, and a high ACOT for some biologic therapies currently on the market and in late-stage development.


Reasons to Buy

Key Topics Covered

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Axial Spondyloarthritis: Executive Summary

2.1 Axial Spondyloarthritis Market to Experience Mild Growth from 2018-2028

2.2 Late-Stage Pipeline Product Launches Will Result in New Players Establishing Themselves

2.3 Persistent Unmet Needs Will Be Addressed Over the Forecast Period

2.4 Interleukin Inhibitors and Janus Kinase Inhibitors Dominate the Axial Spondyloarthritis Pipeline

2.5 What Do Physicians Think?

3 Introduction

3.1 Catalyst

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

4.2 Classification or Staging Systems

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.4.1 Sources

5.4.2 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of AS - Base Scenario

5.4.3 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of Nr-AxSpA - Base Scenario

5.4.4 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of AS - Alternative Scenario

5.4.5 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of Nr-AxSpA - Alternative Scenario

5.4.6 Forecast Assumptions and Methods, HLA-B27 Seropositivity Among Diagnosed AS Patients

5.5 Epidemiological Forecast for AS and Nr-AxSpA (2018-2028) - Base Scenario

5.5.1 Diagnosed Prevalent Cases of AS

5.5.2 Diagnosed Prevalent Cases of Nr-AxSpA

5.6 Epidemiological Forecast for AS and Nr-AxSpA (2018-2028) - Alternative Scenario

5.6.1 Diagnosed Prevalent Cases of AS

5.6.2 Age-Specific Diagnosed Prevalent Cases of AS

5.6.3 Sex-Specific Diagnosed Prevalent Cases of AS

5.6.4 Diagnosed Prevalent Cases of AS by HLA-B27 Seropositivity

5.6.5 Diagnosed Prevalent Cases of Nr-AxSpA

5.6.6 Age-Specific Diagnosed Prevalent Cases of Nr-AxSpA

5.6.7 Sex-Specific Diagnosed Prevalent Cases of Nr-AxSpA

5.7 Discussion

5.7.1 Epidemiological Forecast Insight

5.7.2 Limitations of the Analysis

5.7.3 Strengths of the Analysis

6 Disease Management

6.1 Diagnosis and Treatment Overview

6.2 US

6.3 5EU

6.4 Japan

7 Competitive Assessment

7.1 Overview

7.2 Biosimilars in the Axial Spondyloarthritis Market

7.2.1 Marketed Biosimilars

7.2.2 Pipeline Biosimilars

7.3 Payer Insight

8 Unmet Needs and Opportunity Assessment

8.1 Overview

8.2 Improved Time to Diagnosis

8.3 Patients Refuse Biologic Treatment

8.4 Addressing Drug Treatment Failure

8.5 Identifying Biomarkers of Drug Response

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

9.3 Payer Insight

10 Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 Company Profiles

10.3.1 AbbVie

10.3.2 UCB

10.3.3 Janssen Biotech

10.3.4 Eli Lilly

10.3.5 Kyowa Hakko Kirin

10.3.6 Novartis

10.3.7 Pfizer

11 Market Outlook

11.1 Global Markets

11.1.1 Forecast

11.1.2 Drivers and Barriers - Global Issues

11.2 US

11.2.1 Forecast

11.2.2 Key Events

11.2.3 Drivers and Barriers

11.3 5EU

11.3.1 Forecast

11.3.2 Key Events

11.3.3 Drivers and Barriers

11.4 Japan

11.4.1 Forecast

11.4.2 Key Events

11.4.3 Drivers and Barriers

12 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/nhr0bt

View source version on businesswire.com:https://www.businesswire.com/news/home/20191119005704/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 11/19/2019 09:54 AM/DISC: 11/19/2019 09:54 AM